User login
Key clinical point: After the first screening round, carriers of MSH2 and MSH6 pathogenic variants had a higher incidence of prostate cancer vs age-matched noncarrier controls.
Major finding: Men with MSH2 (P = .011) and MSH6 (P = .034) carriers showed a higher incidence of prostate cancer (prostate-specific antigen [PSA] threshold of 3 ng/mL or higher) vs noncarrier individuals. The overall positive predictive value of biopsy using a PSA threshold of 3 ng/mL was 51.4%.
Study details: An international, prospective IMPACT study of 644 men without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene and 184 age-matched male controls without a familial pathogenic variant in these genes.
Disclosures: This study was supported by Cancer Research UK, the Ronald and Rita McAulay Foundation, and others. The authors received honoraria and/or speaker fees and reported owning patents licensed to and stocks in Arctic Partners.
Source: Bancroft EK et al. Lancet Oncol. 2021 Oct 19. doi: 10.1016/S1470-2045(21)00522-2.
Key clinical point: After the first screening round, carriers of MSH2 and MSH6 pathogenic variants had a higher incidence of prostate cancer vs age-matched noncarrier controls.
Major finding: Men with MSH2 (P = .011) and MSH6 (P = .034) carriers showed a higher incidence of prostate cancer (prostate-specific antigen [PSA] threshold of 3 ng/mL or higher) vs noncarrier individuals. The overall positive predictive value of biopsy using a PSA threshold of 3 ng/mL was 51.4%.
Study details: An international, prospective IMPACT study of 644 men without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene and 184 age-matched male controls without a familial pathogenic variant in these genes.
Disclosures: This study was supported by Cancer Research UK, the Ronald and Rita McAulay Foundation, and others. The authors received honoraria and/or speaker fees and reported owning patents licensed to and stocks in Arctic Partners.
Source: Bancroft EK et al. Lancet Oncol. 2021 Oct 19. doi: 10.1016/S1470-2045(21)00522-2.
Key clinical point: After the first screening round, carriers of MSH2 and MSH6 pathogenic variants had a higher incidence of prostate cancer vs age-matched noncarrier controls.
Major finding: Men with MSH2 (P = .011) and MSH6 (P = .034) carriers showed a higher incidence of prostate cancer (prostate-specific antigen [PSA] threshold of 3 ng/mL or higher) vs noncarrier individuals. The overall positive predictive value of biopsy using a PSA threshold of 3 ng/mL was 51.4%.
Study details: An international, prospective IMPACT study of 644 men without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene and 184 age-matched male controls without a familial pathogenic variant in these genes.
Disclosures: This study was supported by Cancer Research UK, the Ronald and Rita McAulay Foundation, and others. The authors received honoraria and/or speaker fees and reported owning patents licensed to and stocks in Arctic Partners.
Source: Bancroft EK et al. Lancet Oncol. 2021 Oct 19. doi: 10.1016/S1470-2045(21)00522-2.